TScan Therapeutics Q2 EPS $(0.28), Inline, Sales $3.076M Beat $1.405M Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings BeatsNews
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $3.076
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $3.076 million which beat the analyst consensus estimate of $1.405 million by 118.93 percent. This is a 473.88 percent increase over sales of $536.000 thousand the same period last year.